Plain-English translation of NCT05342584 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing venetoclax, a newer medication, given together with standard chemotherapy drugs ( and ) to treat acute myeloid leukemia and advanced myelodysplastic syndrome in adults. Researchers want to find the safest and most effective doses of this combination, and to see how well it works at putting the cancer into remission. The study will also track how long patients stay in remission and look for signs that the leukemia cells have been completely eliminated.
Acute myeloid leukemia is a serious blood cancer, and while chemotherapy has been the standard treatment for decades, doctors are looking for ways to improve outcomes. This medication has shown promise in other blood cancers, and combining it with traditional chemotherapy may help more patients achieve lasting remissions.
You likely qualify if…
You likely don't qualify if…
You will receive the treatment in phases: first, an induction phase where you take venetoclax by mouth (starting at lower doses and building up) while receiving chemotherapy drugs by IV infusion over several days, followed by a high-dose chemotherapy phase. The study starts with smaller groups of patients to find the safest dose, then treats more patients at that dose. You will have frequent blood tests and medical visits to monitor how you're tolerating the treatment and how well it's working against your leukemia.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States